Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.845 USD | +12.50% | +19.87% | -38.87% |
Apr. 11 | Ocuphire Pharma Enrolls 1st Patient in Phase 3 Trial of Visual Acuity Treatment | MT |
Apr. 11 | Ocuphire Pharma, Inc. Announces Global License Agreement with Viatris Inc | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.87% | 42M | |
+29.69% | 699B | |
+25.07% | 571B | |
-4.76% | 364B | |
+17.69% | 326B | |
+3.51% | 286B | |
+14.68% | 236B | |
+4.71% | 198B | |
-12.43% | 194B | |
-3.68% | 154B |
- Stock Market
- Equities
- OCUP Stock
- News Ocuphire Pharma, Inc.
- Ocuphire Pharma Appoints George Magrath as Chief Executive